Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
Phase 3 Recruiting
420 enrolled
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Phase 2 Recruiting
48 enrolled
ARCH
Phase 3 Recruiting
390 enrolled
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
Phase 2 Recruiting
108 enrolled
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Phase 1 Recruiting
21 enrolled
I-SPY
Phase 2 Recruiting
5,000 enrolled
CEMI-first
Phase 2 Recruiting
34 enrolled
ANCHOR
Phase 1 Recruiting
97 enrolled
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Phase 1/2 Recruiting
31 enrolled
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Phase 2 Recruiting
10 enrolled
MINIMA
Phase 2 Recruiting
32 enrolled
LAG-BOOST
Phase 2 Recruiting
72 enrolled
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Phase 1/2 Recruiting
370 enrolled
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Phase 3 Recruiting
369 enrolled
GAP Cemi
Phase 2 Recruiting
20 enrolled
N-PLANC
Phase 2 Recruiting
60 enrolled
ICARS
Phase 2 Recruiting
136 enrolled
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Phase 2 Recruiting
120 enrolled
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
Phase 2 Recruiting
21 enrolled
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Phase 3 Recruiting
560 enrolled
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
Phase 2 Recruiting
40 enrolled
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Recruiting
120 enrolled
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Phase 2 Recruiting
20 enrolled
SPORADIC
Phase 2 Recruiting
152 enrolled
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Phase 1 Recruiting
90 enrolled
COMBINE-EGFR-1
Phase 1/2 Recruiting
933 enrolled
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
Phase 1/2 Recruiting
60 enrolled
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
Phase 2 Recruiting
11 enrolled
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Phase 1 Recruiting
317 enrolled
THIO Sequenced With Cemiplimab in Advanced NSCLC
Phase 2 Recruiting
227 enrolled
Trial of INI-4001 in Patients With Advanced Solid Tumours
Phase 1 Recruiting
50 enrolled
SWITCH
Phase 2 Recruiting
43 enrolled
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Phase 3 Recruiting
300 enrolled
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Phase 2 Recruiting
40 enrolled
ON-5001
Phase 1 Recruiting
168 enrolled
BrILliance
Phase 1/2 Recruiting
240 enrolled
LIMITLESS
Phase 3 Recruiting
30 enrolled
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Phase 2 Recruiting
32 enrolled
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Phase 1/2 Recruiting
890 enrolled
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Phase 1/2 Recruiting
612 enrolled
PALACE
Phase 2 Recruiting
63 enrolled
LuCa-MERIT-1
Phase 1 Recruiting
280 enrolled
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Phase 1/2 Recruiting
345 enrolled
NEO-COMBATXL
Phase 1 Recruiting
12 enrolled
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
Phase 2 Recruiting
50 enrolled
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Phase 2 Recruiting
112 enrolled
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Phase 1 Recruiting
127 enrolled
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Phase 1/2 Recruiting
126 enrolled
INTERVAL
Phase 2 Recruiting
31 enrolled
VIRO-25
Phase 2 Recruiting
142 enrolled